Objectives: Gastric endoscopic submucosal dissection (ESD) is currently a
standard procedure. ESD enables en-bloc resection of large lesions, while
inducing larger artificial ulcers to a greater extent than conventional procedures.
Several studies have reported that proton pump inhibitors (PPIs) prevent delayed bleeding
and expedite the artificial ulcer healing process. Esomeprazole, an
S-isomer of omeprazole, is reportedly one of strongest inhibitors of
gastric acid secretion. Previous studies have examined the effectiveness of esomeprazole.
Our goal was to verify the effects of esomeprazole on artificial ulcers in a prospective
study.Methods: A total of 185 patients underwent ESD for gastric neoplasms at our
hospital between January 2013 and June 2015. Among these 185 patients, 49 post-ESD scar
lesions were included in this prospective trial. First, 20 mg esomeprazole was orally
administered to all subjects before and after the procedure. We then evaluated the delayed
bleeding rate and ulcer scarring rates at 4 weeks and 8 weeks after the procedure by using
a gastric ulcer stage system.Results: There was one case of delayed bleeding (2.0%). Regardless of
Helicobacter pylori infection status, ulcer scarring rates at weeks 4
and 8 were respectively 28.6% (14/49) and 98% (48/49).Conclusions: Our results suggest that oral administration of esomeprazole
alone may be sufficient for prompt healing of artificial gastric ulcers induced by ESD
(UMIN000009367).